Recent Updates
Recently added Catalysts
SYRE

RESIGNATION LETTER

Key Takeaway: Aeglea BioTherapeutics, Inc. To the Board of Directors: Effective as of the date written above, I hereby voluntarily resign (i) as a member of the Board of Directors (the Board ) of Aeglea BioTherapeutics, Inc. (together with its subsidiaries, the Company ) and as a member of

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+249%
120-day peak, hindsight
Typical move
3.2%
average across 3 past catalysts
Cash runway
~49 mo
Minimal dilution risk
Lead asset
Co-ArgI-PEG modified human arginase I
Phase 2 · Acute Myeloid Leukemia

Full Press Release Details

Aeglea BioTherapeutics, Inc.
To the Board of Directors:
Effective as of the date written above, I hereby voluntarily resign (i) as a member of the Board of Directors (the Board ) of
Aeglea BioTherapeutics, Inc. (together with its subsidiaries, the Company ) and as a member of each committee of the Board on which I may serve and (ii) from any and all officer and employment positions of the Company,
including without limitation as the Chief Executive Officer of the Company.
Sincerely,
/s/ David G. Lowe
David G. Lowe
Last updated: Jul 18, 2017